CD274 and cancer: However, although antibody drugs have been used wildly in the clinical cure, the curative effective is still not satisfied enough, the effective rate of PD-1/PD-L1 inhibitor treatment is only 20%-40% in many solid tumors (15, 16), which emphasizes the necessity of developing new immune checkpoints to predict the prognosis of cancer immunotherapy.